New Gilead analysis says remdesivir can reduce deaths, but company says discovery “requires confirmation”


Actions de Gilead Sciences Inc. GILD,
+ 1.88%
gained 2.0% in trade before placing on the market on Friday after the pharmacist released the results of a new analysis of previously released clinical trial data which found that experimental treatment with remdesivir may reduce the risk of COVID-19 patient mortality of 62%, compared to the standard of caring. Gilead said the mortality data point is “an important finding that requires confirmation in prospective clinical trials”. The new analysis is not from a randomized, placebo-controlled clinical trial; it follows from a comparative and pre-planned analysis of 312 critically ill participants in a randomized open-label phase 3 trial and an actual retrospective cohort of 818 patients with COVID-19 who had clinical attributes similar to those included in the trial and received remdesivir as part of their treatment. New analysis may also help reinforce previous findings from a National Institutes of Health randomized, placebo-controlled trial that found that remdesivir can shorten recovery times, a finding released in April that helped the decision from the Food and Drug Administration in May to grant emergency use authorization for remdesivir. Gilead’s stock has gained 14.9% since the start of the year, while the S&P 500 SPX,
+ 0,16%
is down 2.4%.


Please enter your comment!
Please enter your name here